NSE · Healthcare · Biotechnology
EPS came in at 2.04 against a street estimate of 3.46 — a miss of 41.0%.
with an average price target of ₹165.00.
| Document | Date |
|---|---|
| Annual report FY2026 DISHMAN CARBOGEN AMCIS LIMITED - ANNUAL REPORT FY26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹29,319 million (₹2,931.9 crores), up 8.1% Y | 2026-09-05 |
| Q1 FY27 earnings call DISHMAN CARBOGEN AMCIS LIMITED - Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue for Q1 FY27 (quarter ending June 30, 2026): INR 6,776 million vs INR 7,0 | 2026-08-21 |
| Investor presentation · Q1 FY27 DISHMAN CARBOGEN AMCIS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Net Revenue Q1 FY27: ₹6,776 million, down 4.3% YoY from ₹7,081 million in Q1 FY2 | 2026-08-17 |
| Quarterly results · Q1 FY27 DISHMAN CARBOGEN AMCIS LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Consolidated Revenue (Q1 FY2027): ₹677.64 crores vs ₹708.05 crores ( | 2026-08-14 |
| Quarterly results · Q4 FY26 DISHMAN CARBOGEN AMCIS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue (Consolidated, FY2026): INR 2,931.90 crores (vs INR 2,711.50 cro | 2026-06-22 |
| Q4 FY26 earnings call DISHMAN CARBOGEN AMCIS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 851 crores (19% growth vs INR 716 crores in Q4 FY25) • Full | 2026-05-25 |
| Investor presentation DISHMAN CARBOGEN AMCIS LIMITED – INVESTOR SUMMARY Q4 FY26 & FY26 (Year ended March 31, 2026) --- HEADLINE NUMBERS • FY26 Net Revenue: ₹29,319 mn (u | 2026-05-20 |
| Q3 FY26 earnings call DISHMAN CARBOGEN AMCIS LIMITED – Q3 FY26 SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 720 crores vs INR 682 crores in Q3 FY25 (5.5% growth) • 9-M | 2026-02-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Dishman Carbogen Amcis Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.